FLIBANSERIN: A Happy Ending Solution to Hypoactive Sexual Desire Disorder
Hypoactive sexual desire disorder (HSDD) is a persistent or recurrent deficiency or absence of sexual desire. It can cause prominent distress and interpersonal difficulty of women. There have been drugs available to treat sexual disorders in men when there is no such drug for women. Nowadays, FDA approved Flibanserin to treat HSDD of premenopausal women. This drug Flibanserin has no novel mechanism of action but the possible mechanism of action is modulating serotonin and dopamine activity in brain parts as balance of these systems is significance for a normal sexual response.
Keywords: Hypoactive Sexual Desire Disorder, Premenopausal women, Flibanserin
2. Clayton AH, DeRogatis LR, Rosen RC, Pyke R. Intended or unintended consequences? The likely implications of raising the bar for sexual dysfunction diagnosis in the proposed DSM-V revisions: 1. For women with incomplete loss of desire or sexual receptivity. J Sex Med 2012; 9:2027â€“39.
3. Basson R, Driscoll M, Correia S. Flibanserin for Low Sexual Desire in Women: A Molecule from Bench to Bed? EBioMedicine. 2015; 2(8):772-773.
4. Gohil K. Pharmaceutical Approval Update. Pharmacy and Therapeutics. 2015; 40(10):649-689.
5. Uphouse L. Pharmacology of serotonin and female sexual behavior. Pharmacology, biochemistry, and behavior. 2014; 0:31-42.
6. Zakiniaeiz Y, Cosgrove KP, Potenza MN, Mazure CM. Balance of the Sexes: Addressing Sex Differences in Preclinical Research. The Yale Journal of Biology and Medicine. 2016; 89(2):255-259.
7. Chilmonczyk Z, Bojarski AJ, Pilc A, Sylte I. Functional Selectivity and Antidepressant Activity of Serotonin 1A Receptor Ligands. Hashimoto K, ed. International Journal of Molecular Sciences. 2015; 16(8):18474-18506.
8. Sang JH, Kim T-H, Kim SA. Flibanserin for Treating Hypoactive Sexual Desire Disorder. Journal of Menopausal Medicine. 2016; 22(1):9-13.
9. Stahl SM. Mechanism of action of ï¬‚ibanserin, a multifunctional serotonin agonist and antagonist (MSAA), in hypoactive sexual desire disorder. CNS Spectr 2015; 20:1â€“6.
10. Nappi RE. Why are there no FDA-approved treatments for female sexual dysfunction? Expert Opin Pharmacother 2015; 16:1735â€“8.
11. Levine SB. Flibanserin. BMJ 2015; 350:h3097.
12. UphouseL. Pharmacology of serotonin and female sexual behavior. Pharmacology, biochemistry, and behavior. 2014; 0:31-42.
13. ZhenliGao, Diandong Yang, Luxin Yu, MD, Yuanshan Cui. Efficacy and Safety of Flibanserin in Women with Hypoactive Sexual Desire Disorder: A Systematic Review and Meta-Analysis.J Sex Med 2015; 12:2095â€“2104.
14. Thorp J, Simon J, Dattani D, Taylor L, Kimura T, Garcia MJ, Lesko L, Pyke R. Treatment of hypoactive sexual desire disorder in premenopausal women: Efï¬cacy of ï¬‚ibanserin in the DAISY study. J Sex Med 2012; 9:793â€“804.
15. Derogatis LR, Komer L, Katz M, Moreau M, Kimura T, Garcia MJ, Wunderlich G, Pyke R. Treatment of hypoactive sexual desire disorder in premenopausal women: Efï¬cacy of ï¬‚ibanserin in the VIOLET Study. J Sex Med 2012; 9:1074â€“85.
16. Katz M, DeRogatis LR, Ackerman R, Hedges P, Lesko L, Garcia MJ, Sand M. Efï¬cacy of ï¬‚ibanserin in women with hypoactive sexual desire disorder: Results from the BEGONIA trial. J Sex Med 2013; 10:1807â€“15.
17. Simon JA, Kingsberg SA, Shumel B, Hanes V, Garcia MJ, Sand M. Efï¬cacy and safety of ï¬‚ibanserin in postmenopausal women with hypoactive sexual desire disorder: Results of the SNOWDROP trial. Menopause 2014; 21:633â€“40.
18. Gohil K. Pharmaceutical Approval Update. Pharmacy and Therapeutics. 015; 40(10):649-689.
19. Addyi Approval History. Available at: https://www.drugs.com/history/addyi.htmlAccessed on 18.08.2016.
20. FDA Approval of Flibanserin â€” Treating Hypoactive Sexual Desire Disorder. Available at: http://www.nejm.org/doi/full/10.1056/NEJMp1513686#t=article Accessed on 18.08.2016.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).